WO2005046607A3 - Combinations for the treatment of proliferative diseases - Google Patents

Combinations for the treatment of proliferative diseases Download PDF

Info

Publication number
WO2005046607A3
WO2005046607A3 PCT/US2004/037527 US2004037527W WO2005046607A3 WO 2005046607 A3 WO2005046607 A3 WO 2005046607A3 US 2004037527 W US2004037527 W US 2004037527W WO 2005046607 A3 WO2005046607 A3 WO 2005046607A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
proliferative diseases
combinations
cancer
drugs
Prior art date
Application number
PCT/US2004/037527
Other languages
French (fr)
Other versions
WO2005046607A2 (en
Inventor
M. James Nichols
Margaret S. Lee
Curtis Keith
Yanzhen Zhang
Original Assignee
Combinatorx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by Combinatorx, Inc. filed Critical Combinatorx, Inc.
Priority to BRPI0416390-7A priority Critical patent/BRPI0416390A/en
Priority to JP2006539813A priority patent/JP2007524657A/en
Priority to AU2004289311A priority patent/AU2004289311A1/en
Priority to CA002545423A priority patent/CA2545423A1/en
Priority to EP04810676A priority patent/EP1689352A2/en
Publication of WO2005046607A2 publication Critical patent/WO2005046607A2/en
Priority to IL175611A priority patent/IL175611A0/en
Priority to NO20062358A priority patent/NO20062358L/en
Priority to IS8496A priority patent/IS8496A/en
Publication of WO2005046607A3 publication Critical patent/WO2005046607A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention features combinations of drugs for the treatment of proliferative diseases (e.g., cancer). The invention also features methods for identifying new combination therapies for the treatment of cancer and other proliferative diseases.
PCT/US2004/037527 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases WO2005046607A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0416390-7A BRPI0416390A (en) 2003-11-12 2004-11-09 combinations for treating proliferative diseases
JP2006539813A JP2007524657A (en) 2003-11-12 2004-11-09 Combination methods for the treatment of proliferative diseases
AU2004289311A AU2004289311A1 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases
CA002545423A CA2545423A1 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases
EP04810676A EP1689352A2 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases
IL175611A IL175611A0 (en) 2003-11-12 2006-05-11 Combinations for the treatment of proliferative diseases
NO20062358A NO20062358L (en) 2003-11-12 2006-05-23 Combinations for the treatment of proliferative diseases
IS8496A IS8496A (en) 2003-11-12 2006-06-02 Compositions for the Treatment of Propagating Diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US60/519,551 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases
US10/855,130 2004-05-27

Publications (2)

Publication Number Publication Date
WO2005046607A2 WO2005046607A2 (en) 2005-05-26
WO2005046607A3 true WO2005046607A3 (en) 2012-12-20

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037527 WO2005046607A2 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases

Country Status (13)

Country Link
EP (1) EP1689352A2 (en)
JP (1) JP2007524657A (en)
KR (1) KR20060118514A (en)
AR (1) AR046841A1 (en)
AU (1) AU2004289311A1 (en)
BR (1) BRPI0416390A (en)
CA (1) CA2545423A1 (en)
IL (1) IL175611A0 (en)
IS (1) IS8496A (en)
NO (1) NO20062358L (en)
RU (1) RU2006120491A (en)
TW (1) TW200526777A (en)
WO (1) WO2005046607A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070865A1 (en) * 2008-03-18 2010-05-12 Genentech Inc COMBINATIONS OF AN ANTIBODY-ANTI-HER2 PHARMACO AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066037A2 (en) * 1998-06-17 1999-12-23 Recherches Expertises Et Developpement Medicaux Parenz Inc. Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066037A2 (en) * 1998-06-17 1999-12-23 Recherches Expertises Et Developpement Medicaux Parenz Inc. Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORISY ET AL.: "Systematic discovery of multicomponent therapeutics", PNAS, vol. 100, no. 13, 24 June 2003 (2003-06-24), pages 7977 - 7982, XP009061663, DOI: doi:10.1073/pnas.1337088100 *
DIAMOND ET AL.: "PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, June 1994 (1994-06-01), pages 3752 - 3762 *
KAISER ET AL.: "All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 18925 - 18931, XP002166152, DOI: doi:10.1074/jbc.274.27.18925 *

Also Published As

Publication number Publication date
IS8496A (en) 2006-06-02
JP2007524657A (en) 2007-08-30
RU2006120491A (en) 2007-12-20
KR20060118514A (en) 2006-11-23
IL175611A0 (en) 2008-04-13
EP1689352A2 (en) 2006-08-16
TW200526777A (en) 2005-08-16
NO20062358L (en) 2006-07-12
CA2545423A1 (en) 2005-05-26
AU2004289311A1 (en) 2005-05-26
AR046841A1 (en) 2005-12-28
WO2005046607A2 (en) 2005-05-26
BRPI0416390A (en) 2007-02-21

Similar Documents

Publication Publication Date Title
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
WO2002099055A3 (en) Cips as modifiers of the p53 pathway and method of use
WO2007059041A3 (en) Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2006002437A3 (en) Treatment of conditions involving demyelination
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005117938A3 (en) Methods of treating ocular conditions
WO2003080582A3 (en) Fredericamycin derivatives
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2003087831A3 (en) Proteins involved in breast cancer
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2006052810A3 (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2006045476A3 (en) Gpr17 modulators, method of screening and uses thereof
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2003073818A3 (en) Proteomic analysis of tumors for development of consultative report of therapeutic options
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004289311

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2545423

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 547123

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005456

Country of ref document: MX

Ref document number: 2006539813

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 175611

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020067010335

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004289311

Country of ref document: AU

Date of ref document: 20041109

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004289311

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004810676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006120491

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200480039985.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004810676

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010335

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0416390

Country of ref document: BR